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Vitamin A (retinol), its metabolites and analogues have been heavily focused 
upon due to their clinical value and utility. Retinol can be used as a reflection 
of dietary or nutritional status, while the retinol analogues (isotretinoin, 
tretinoin, etretinate) are being proven as potent dermatologic and anti-tumor 
agents. High-performance liquid chromatography (HPLC) has been 
demonstrated to be applicable to the measurement of these compounds in 
blood. HPLC assays have been reported for retinol [l--4], 13&s-retinoic acid 
[ 5, 61, all-trtrns-retinoic acid [ 7, 81, etretinate [ 9, lo] , plus retinol and retinal 
isomers [ ll---151. Several assay systems have been reported for the isocratic 
separation of mixtures of retinoids [ 13-151. Of these, the methods of Frolick 
et al. [ 141 and McClean et al. [15] allow for the measurement of numerous 
retinoids in biological specimens through the use of single isocratic systems. 
Using these methods the required time for separation of compounds can run as 
long as 36 min [14]. The natural and synthetic retinoids, plus their respective 
major metabolites, have differences in polarity that make chromatographic 
separation difficult in a short time period. During the long separation times the 
later elutmg peaks become broad and require an integrator. To counteract this 
037%4347/84/$03.00 0 1984 Elsevier Science Publishers B.V. 
200 
problem solvent programming has been successfully applied to the mdysis of 
13-czs-retinoic acid and 4-oxo-13cisretinoic acid in blood samples [ 51. 
In this report we describe a programmed gradient HPLC system for the 
analysis of multiple retinoids, including retinol, retinal, 13-cis-retinoic acid 
(isotretinoin) and its metabolite, all-truns-retinoic acid (tretinoin), etretinate and 
its metabolites. The use of gradient elution significantly shortens the analysis 
time, and results in sharp symmetrical peaks which can be measured without 
an integrator or data module. 
EXPERIMENTAL 
Reagents 
All reagents were of analytical-reagent grade. Acetonitrile was from Burdick 
and Jackson Labs. (Muskegon MI, U.S.A.). Glacial acetic acid was from 
Mallinckrodt (Paris, MO, U.S.A.). Retinol, all-truns-retinoic acid, retinal, and 
retinyl acetate were purchased from Sigma (St, Louis MO, U.S.A.). 13&s- 
Retinoic acid, etretinate, and Ro lo-1670 were gifts from Hoffmann-La Roche 
(Nutley NJ, U.S.A.). 
Chromatography 
Measurements were made using a Vanan Model 5000 liquid chromatograph 
equippped with a UV-50 variable-wavelength detector. A Whatman lo-pm 
Partisil PXS lo/25 ODS-2 column (Whatman, Clifton, NJ, U.S.A.) was used. 
The programmed mobile phase consisted of a combination of two solutions. 
Solution A consisted of 0.5% (v/v) acetic acid in acetonitrile. Solution B 
consisted of 0.5% acetic acid in water. The instrument parameters and program 
are outlined in Table I. A linear gradient was used between T4 mb and T6 mb, 
The total run time was 11 min, resulting in a 5-min hold at the final conditions. 
A 5-mm equilibration time was used between injections. 
TABLE I 
INSTRUMENTAL PARAMETERS 
Flow-rate 3.0 ml/min 
Temperature ambient 
Absorbance 360 nm (UV), 0.05 a.u.f.s. 
Mobile phase T, mh 80% A, 20% B 
T 4.0min 80% A, 20% B 
T 6.0min 90% A, 10% B 
T ll.omm 90% A, 10% B 
Specimen preparation 
The extraction procedure used was similar to that outlined by Puglisi and de 
Silva [ 13 1, with a single modification. A l-ml volume of blood or serum was 
placed in a 15-ml screw-top tube. To this 50 ~1 of retinyl acetate, 10 mg/l in 
acetonitrile, were added as internal standard. After vortexing, 2.5 ml of 1 M 
phosphate buffer, pH 6.0, were added. Following a short vortex, 6 ml of 
diethyl ether were added. The tube was capped and placed on an Eberbach 
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mechanical shaker (Eberbach, Ann Arbor, MI, U.S.A.) for 15 min at 180 
strokes per min. Following centnfugation the ether layer was then removed and 
evaporated to dryness under nitrogen. The residue was dissolved in 100 ~1 of 
solution A. A 50+1 aliquot was injected for analysis. 
Calculations 
Three blood or serum standards of 250, 500, and 1000 ng/ml (500, 1000, 
2000 ng/ml for retinol) were prepared for each compound using 500 pg/ml 
stock standards in acetonitrile. Calibration curves were made by determining 
peak height ratios relative to the internal standard. 
RESULTS AND DISCUSSION 
Typical chromatograms for standard solutions and patient specimens 
shown in Fig. 1. As can be observed from Fig, 1, excellent separation of 
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Fig. 1. Reversed-phase chromatograms for whole blood specimens containing retinoids; (A) 
blood spiked with standards (all-truns-retinoic aicd and etretinate, 500 ng/ml; 13-cis-retinoic 
acid and retinol, 2000 ng/ml), (B) normal individual, (C) blood from patient receiving 
multiple-dose isotretinoin, (D) blood from patient receiving multiple-dose etretinate therapy. 
Absorbance setting is 0.05 a.u.f.s. for A, B and D, 0.10 for C. 
TABLE II 
RETENTION TIMES AND RECOVERY FOR RETINOIDS 




Ro lo-1670 4.1 78+ 5 
13-cis-Retinoic acid 5.1 98* 5 
All-trans-retionic acid 6.9 94+ 7 
Retinol 7.9 86 + 13 
Etretinate 9.1 77 + 11 
Retinyl acetate 9.9 70* 5 
Peak 2 3.2 - 
Peak 3 1.6 - 
*Average based on 22 extractions and analyses of a 500 ng/ml blood standard of each com- 
pound. This concentratmn approximates a low-normal value for retinol [ 151, and a 
therapeutic level for etretinate [ 161. 
compounds can be achieved using the chromatographic system described here. 
Although retinal will overlap with etretinate to some extent, this will cause no 
problem since the normal concentration in blood specimens is too minimal 
to cause any interference in the determination of etretinate levels. The actual 
retention times and analytic recoveries are summarized in Table II. 
In addition to the presence of etretinate in the blood of patients receiving 
this drug, at least two metabolites are also found. One of these is Ro 10-1670, 
the acid metabolite of the parent compound [16, 171 that is also potentially 
active. However, as has been observed by Hilnni et al. [lo] and McClean et al. 
[15], a second metaboiite is also evident. This metabolite is Ro 13-7652, the 
13-ci.s isomer of Ro 10-1670. The peak height of this second metabolite was 
consistently larger than the Ro lo-1670 peak in blood samples from patients 
on chronic etretinate therapy. The exact clinical importance of this metabolite 
is currently under study. In addition to these two previously observed 
metabolites, a third metabolite can also be observed. This compound, labelled 
as peak 3 in Fig. lD, seems to parallel the level of the other two metabolites in 
blood from individuals receiving this drug. This peak was not observed in blood 
from control individuals, nor in specimens taken from individuals receiving 
placebos during therapeutic trials. When individuals are removed from etretinate 
therapy, this peak disappears. This metabolite is most probably the 4-hydroxy- 
phenyl retinoic acid analogue, Ro 12-7310, an active major metabolite of 
etretinate [ 181 . 
In patients receiving isotretinoin (13-cis-retinoic acid) this assay clearly 
separates and defines both the parent compound and metabolite, 4-oxo-iso- 
tretinoin [ 191. The concentration of the metabolite exceeds that of the parent 
compound 6 h after a single dose [ 16 J or during chronic drug therapy (Fig. 1). 
McClean et al. [15] have also been able to observe 4-oxo-isotretinoin in patient 
specimens using HPLC, although the metabolite elutes on the down-side of the 
solvent front in their system. This could potentially make quantitation 
difficult. The large solvent front is probably due to the extraction system used. 
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Although not as rapid as the extraction procedure just discussed above, the 
method of Puglisi and De Silva [ 131, as utilized in our assay procedure, results 
in a small solvent front. This allows for an accurate quantitation of 4-0x0- 
Isotretinoin. In addition the results obtained are unaffected by variations in 
specimen type. The method presented here works equally well on whole blood, 
serum, hemolyzed specimens, or plasma collected with any common 
anticoagulant. The inter- and intra-assay variability (coefficient of variation) for 
all compounds was less than 10%. 
Due to photodecomposition of retinoids, care must be taken to protect 
samples from direct contact with light. In our laboratory, extraction and 
analysis are performed in a darkened room with only a minimum of diffuse 
light allowed. Extraction tubes were wrapped with aluminum foil so as to 
protect the retinoid compounds. 
The assay described here is optimized for the determination of multiple 
retinoids. The selective determination of retinol in biological specimens can be 
best performed at 324 nm, at which retinol has maximal absorbance, With this 
method proposed here retinol levels can be accurately determined using as little 
as 200 ~1 of serum, making this method applicable to pediatric specimens. 
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